143 related articles for article (PubMed ID: 24166907)
1. The role of protein kinase CK2 in glioblastoma development.
Ji H; Lu Z
Clin Cancer Res; 2013 Dec; 19(23):6335-7. PubMed ID: 24166907
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of casein kinase 2 in glioblastomas: Absence of class restriction and broad therapeutic potential.
Dubois N; Willems M; Nguyen-Khac MT; Kroonen J; Goffart N; Deprez M; Bours V; Robe PA
Int J Oncol; 2016 Jun; 48(6):2445-52. PubMed ID: 27098015
[TBL] [Abstract][Full Text] [Related]
4. Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.
Gowda C; Song C; Kapadia M; Payne JL; Hu T; Ding Y; Dovat S
Adv Biol Regul; 2017 Jan; 63():71-80. PubMed ID: 27666503
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of protein kinase CK2 induces autophagic cell death through modulation of the mTOR and MAPK signaling pathways in human glioblastoma cells.
Olsen BB; Svenstrup TH; Guerra B
Int J Oncol; 2012 Dec; 41(6):1967-76. PubMed ID: 23007634
[TBL] [Abstract][Full Text] [Related]
6. Novel small molecule protein kinase CK2 inhibitors exert potent antitumor effects on T98G and SEGA cells in vitro.
Pucko E; Ostrowski R; Matyja E
Folia Neuropathol; 2019; 57(3):239-248. PubMed ID: 31588710
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
8. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase CK2 is required for the recruitment of 53BP1 to sites of DNA double-strand break induced by radiomimetic drugs.
Guerra B; Iwabuchi K; Issinger OG
Cancer Lett; 2014 Apr; 345(1):115-23. PubMed ID: 24333722
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
[TBL] [Abstract][Full Text] [Related]
11. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma.
Ferrer-Font L; Alcaraz E; Plana M; Candiota AP; Itarte E; Arús C
Pathol Oncol Res; 2016 Jul; 22(3):633-7. PubMed ID: 26466942
[TBL] [Abstract][Full Text] [Related]
12. Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion.
Pattwell SS; Holland EC
Trends Mol Med; 2017 Sep; 23(9):773-776. PubMed ID: 28774478
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
Dovat E; Song C; Hu T; Rahman MA; Dhanyamraju PK; Klink M; Bogush D; Soliman M; Kane S; McGrath M; Ding Y; Desai D; Sharma A; Gowda C
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467550
[TBL] [Abstract][Full Text] [Related]
14. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
15. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
16. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Prins RC; Burke RT; Tyner JW; Druker BJ; Loriaux MM; Spurgeon SE
Leukemia; 2013 Oct; 27(10):2094-6. PubMed ID: 23900138
[No Abstract] [Full Text] [Related]
17. CK2 inhibition induced PDK4-AMPK axis regulates metabolic adaptation and survival responses in glioma.
Dixit D; Ahmad F; Ghildiyal R; Joshi SD; Sen E
Exp Cell Res; 2016 May; 344(1):132-142. PubMed ID: 27001465
[TBL] [Abstract][Full Text] [Related]
18. An Experimenter's Guide to Glioblastoma Invasion Pathways.
de Gooijer MC; Guillén Navarro M; Bernards R; Wurdinger T; van Tellingen O
Trends Mol Med; 2018 Sep; 24(9):763-780. PubMed ID: 30072121
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
